International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2025   Volume 15   Issue 2

Rebuilding SAR from Fragmented Natural Product Evidence across Chemical Series, Assay Systems, Targets, and Contexts
Download PDF


, ,
  1. Department of Structure–Activity Relationship Reconstruction, Faculty of Pharmacy, University of Ghana, Accra, Ghana.
  2. Department of Fragmented Evidence Integration for SAR, Faculty of Pharmacy, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Citation
Vancouver
Osei D, Afriyie A, Adu K. Rebuilding SAR from Fragmented Natural Product Evidence across Chemical Series, Assay Systems, Targets, and Contexts. Int J Pharm Phytopharmacol Res. 2025;15(2):80-9. https://doi.org/10.51847/RfYdbfnUqf
APA
Osei, D., Afriyie, A., & Adu, K. (2025). Rebuilding SAR from Fragmented Natural Product Evidence across Chemical Series, Assay Systems, Targets, and Contexts. International Journal of Pharmaceutical And Phytopharmacological Research, 15(2), 80-89. https://doi.org/10.51847/RfYdbfnUqf
Download citation:   EndNote   RIS
Article Link:
Downloads: 29
Views: 52
Abstract

Structure–activity relationships are usually interpreted within deliberately constructed chemical series measured under reasonably controlled conditions. Natural-product evidence rarely has this architecture. Parent metabolites, congeners, biosynthetic variants, degradation products, semisynthetic derivatives, and mechanistic probes may instead be distributed across different publications, databases, laboratories, assay formats, target constructs, and endpoint definitions. An apparently sparse SAR may therefore represent a fragmented evidence problem in which observations cannot be pooled safely before chemical and experimental context are resolved. This article develops an original evidence-integration framework for rebuilding comparable local SAR from such records. The analysis separates chemical identity, scaffold relationship, assay state, target identity, mechanistic endpoint, potency representation, provenance, inactivity evidence, contradiction, and uncertainty rather than collapsing them into a single activity matrix. The central proposal is that structural relatedness and evidential comparability should be evaluated separately: close analogs can provide weak SAR evidence when experimental contexts differ materially, whereas records from different sources may support a defensible local relationship when identity and context are sufficiently aligned. Reconstructed SAR is therefore treated as context-tagged evidence rather than as a universally harmonized potency surface. The framework is intended to support auditable medicinal-chemistry reasoning and more defensible model training. It is not a validated reconstruction algorithm, does not define universal comparability thresholds, and cannot recover missing experimental states. Genuine activity cliffs, uncertain identities, incomplete metadata, context-dependent pharmacology, and missing negative evidence remain substantive boundaries.

Related articles:
Most viewed articles:
Naproxen in Pain and Inflammation – A Review
Vol 11 Issue 1, 2021 | Svetoslav Nikolaev Stoev
An Overview on Emulgel
Vol 9 Issue 1, 2019 | Sreevidya V.S
Volume 16
Issue 4
2026

Call for Papers
[email protected]
Issues
Associations
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0).

Copyright © 2026 International Journal of Pharmaceutical and Phytopharmacological Research
Authors retain copyright of their article if they are accepted for publication.